Basic view The Company’s raison d'être is to contribute to improving the health of people around the world through the provision of innovative and reliable pharmaceutical products. The Company aims to sustainably enhance corporate value by being chosen and trusted by all stakeholders. With this business philosophy, we work to ensure and strengthen the effectiveness of corporate governance from the following perspectives:
- Ensuring transparency, appropriateness and agility of management; and
- Fulfillment of our fiduciary duties and accountability to shareholders and appropriate collaboration with all stakeholders.
The Company has established the Corporate Governance Guidelines which clarifies the basic views and guidelines that must be followed in order for the Company to ensure and strengthen the effectiveness of corporate governance. The guidelines are posted on the following Company’s website. http://www.astellas.com/en/corporate/pdf/governance_guideline_en.pdf
Summary of the corporate governance system
The summary of the corporate governance systems is as follows:
- The Company adopts the organizational structure of “Company with Audit & Supervisory Board.” Outside Directors and outside Audit & Supervisory Board Members constitute the majority of the Board of Directors and the Audit & Supervisory Board, respectively.
- The Board of Directors principally serves the oversight function of the execution of business, and also makes decisions on important business execution.
- As organs for handling execution of business, the Company establishes the Executive Committee and the Japan Management Committee for discussing important matters, and also appoints Executive Officers who are responsible for their respective assigned departments or functions. The responsibility and authority for the execution of business of the organs described above, the President and CEO and the Executive Officers are clearly stipulated in the Corporate Decision Authority Policy.
- As advisory bodies to the Board of Directors, the Company establishes the Nomination Committee and the Compensation Committee, each of which are composed of a majority of outside Directors.